Butasiv7.5 mg/5 ml

Butasiv 7.5 mg/5 ml is used to relieve dry (non-productive) cough. Dry cough may be caused by a recent viral infection. Butasiv 7.5 mg/5 ml is also used for pre & post-operative cough sedation in patients who will undergo surgical procedures and bronchoscopy. It can be used in the acute cough of any ... Read moreButasiv 7.5 mg/5 ml is used to relieve dry (non-productive) cough. Dry cough may be caused by a recent viral infection. Butasiv 7.5 mg/5 ml is also used for pre & post-operative cough sedation in patients who will undergo surgical procedures and bronchoscopy. It can be used in the acute cough of any etiology, whooping cough and cough due to acute lower respiratory tract infections (tracheitis, laryngitis, bronchitis) etc.

Cough suppressant

Butasiv 7.5 mg/5 ml belongs to the anti-cough medicines of central action. It exerts expectorant, moderate bronchodilating and anti-inflammatory action. Butasiv 7.5 mg/5 ml also increases the spirometery indexes and blood oxygenation. It is safe and non-sedating which is neither chemically nor pharmacologically related to opium alkaloids. The active metabolites of Butasiv 7.5 mg/5 ml have also antitussive action.

Tablet: Adult: 2-3 tablets daily at 8 to 12 hours intervals, Adolescents over 12 years old: 1-2 tablets daily. Syrup: Children (3-6 years): 5 ml 3 times daily, Children (6-12 years): 10 ml 3 times daily, Adolescent: 15 ml 3 times daily, Adult: 15 ml 4 times daily. Pediatric Drops: Children (1-3 years): 0.75 ml 4 times daily, Children (2 months-1 year): 0.50 ml 4 times daily.

Use in adult: Butasiv 7.5 mg/5 ml 50 mg tablet: 2-3 tablets daily. Butasiv 7.5 mg/5 ml syrup: 15 ml 4 times daily. Use in children & adolescents:Butasiv 7.5 mg/5 ml 50 mg tablet: Adolescent over 12 years old: 1-2 tablets daily. Butasiv 7.5 mg/5 ml syrup: Children (3-6 yrs): 5 ml 3 times daily. Children (6-12 yrs): 10 ml 3 times daily. Adolescent: 15 ml 3 times daily. Butasiv 7.5 mg/5 ml pediatric drops: Children ( 2 months- 1 yrs): 0.50 ml 4 times daily. Children (1-3 yrs): 0.75 ml 4 times daily.

Concomitant use with expectorants should be avoided.

Hypersensitivity to the active ingredient.

Tolerance of Butasiv 7.5 mg/5 ml is good.Adverse reactions such as rash,nausea,diarrhoea and vertigo have been observed in a few rare cases,resolving after dose reduction or treatment withdrawal.

Butasiv 7.5 mg/5 ml should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. As a general rule, for safety reasons, in the absence of data on elimination of the active substance in breast milk, the benefits of Butasiv 7.5 mg/5 ml administration during breast feeding should be carefully weighed against the risks.

Butasiv 7.5 mg/5 ml suppresses the cough reflex and therefore the concomitant use with expectorants should be avoided, since it may lead to mucus retention in the airways, which increases the risk of bronchospasm and respiratory infections. If the cough persists for more than 7 days (more than 3 days in children younger than12 years of age) doctor must be consulted.

Accidental overdose with Butasiv 7.5 mg/5 ml can cause the following symptoms: drowsiness, nausea, vomiting, diarrhoea, loss of balance and hypotension. Standard emergency procedures should be followed: activated charcoal, saline laxatives and standard cardio-respiratory resuscitation.

Keep away from light and moisture, store below 30°C. Keep all the medicines out of the reach of children.

Cough suppressant

Butasiv 7.5 mg/5 ml acts directly on the brain's cough center to suppress cough. Butasiv 7.5 mg/5 ml is safe and non-sedating which is neither chemically nor pharmacologically related to opium alkaloids. Butasiv 7.5 mg/5 ml is rapidly and completely absorbed after oral administration. Maximum concentration is reached within 9 hours with the sustained-release tablet. This is extremely protein-bound and plasma elimination half-life is about 13 hours. The active metabolites of Butasiv 7.5 mg/5 ml have also antitussive action.

Butasiv 7.5 mg/5 ml should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. As a general rule, for safety reasons, in the absence of data on elimination of the active substance in breast milk, the benefits of Butasiv 7.5 mg/5 ml administration during breast feeding should be carefully weighed against the risks.